Biomax Informatics software licensed by global pharma company, Boehringer Ingelheim, to build a target discovery knowledge platform
Biomax Informatics AG announces that their longtime client, Boehringer Ingelheim, has signed a multi-year license for the BioXM™ Knowledge Management Environment to support their global target discovery research. In addition, the company has extended their license for Biomax’s BioRS™ Integration and Retrieval System.
Boehringer Ingelheim is using the BioXM™ Knowledge Management Environment to build and maintain a target discovery knowledge platform that supports the company’s research on a global scale. The BioXM platform leverages Boehringer Ingelheim’s existing BioRS infrastructure to semantically integrate information from the company’s in-house systems and other proprietary and public data sources including pathways, compounds, sequences, genotypes, phenotypes, experimental data and text mining results. The BioXM platform allows all of the company’s external applications to access the data either directly or through application programming interfaces (APIs) and automates the updating of all integrated databases on a regular schedule.
“Boehringer Ingelheim has used the BioRS software for data integration for many years. Adding the BioXM software now lets them model their complete target discovery process in one easy-to-use, sustainable knowledge hub,” explained Dr. Kaj Albermann, who manages the Boehringer Ingelheim project at Biomax.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates and a total of around 50,000 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. www.boehringer-ingelheim.com
Biomax Informatics provides computational solutions for better decision making and knowledge management in the life sciences. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes clinics, companies and research organizations that are successful in drug discovery, diagnostics, fine chemicals, food and plant production. www.biomax.com
Biomax, BioRS and BioXM are registered trademarks of Biomax Informatics AG in Germany and other countries. Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.
Biomax Informatics AG
Dr. Philipp Krubasik, +49 89 895574-0
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AURAK15.12.2018 11:51 | Pressemeddelelse
AURAK Gains SACSCOC Accreditation
KRAMER-LEVIN14.12.2018 18:44 | Pressemeddelelse
Lehman Brothers Treasury Announces Plans for Partial Wind-Down
MA-TAKEDA-PHARMACEUTICAL14.12.2018 18:02 | Pressemeddelelse
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
FL-POTNETWORK-HOLDINGS14.12.2018 16:44 | Pressemeddelelse
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules
HENLEY-&-PARTNERS14.12.2018 15:02 | Pressemeddelelse
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth
BOEHRINGER-INGELHEIM14.12.2018 10:09 | Pressemeddelelse
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum